BioVersys AGFRA:W33 -0.71%7 Median PS Value is €0.00 as of Jul. 06, 2026. GuruFocus rates FRA:W33 with a GF Score™ of 7/100. Among 277 Biotechnology companies, BioVersys AG ranks worse than 361010.47% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. BioVersys AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.147. BioVersys AG's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is €0.00.
As of today (2026-07-06), BioVersys AG's share price is €28.00. BioVersys AG's Median PS Value is €0.00. Therefore, BioVersys AG's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for BioVersys AG's Median PS Value or its related term are showing as below:
FRA:W33's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
BioVersys AG (FRA:W33) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
BioVersys AG's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
28.00
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG Median PS Value Related Terms
BioVersys AG Median PS Value Historical Data
* Premium members only.
The historical data trend for BioVersys AG's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG Median PS Value Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
Median PS Value
0.00
0.00
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
Median PS Value
0.00
0.00
0.00
0.00
FRA:W33 vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, BioVersys AG's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where BioVersys AG's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioVersys AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.147.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG (FRA:W33) has a Median PS Value of €0.00 as of Jul. 06, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #999999 out of 277 companies in the Biotechnology industry.
Is BioVersys AG's Median PS Value too high?
BioVersys AG's current Median PS Value is €0.00. Based on the distribution chart, BioVersys AG ranks #999999 out of 277 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVersys AG has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #999999 out of 277 companies for Median PS Value. This places BioVersys AG in the lower half of its industry. The industry median Median PS Value is 0.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.66, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on BioVersys AG and its competitors. For the Biotechnology industry, the median Median PS Value is 0.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVersys AG's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current Median PS Value of €0.00. The current Median PS Value is €0.00. BioVersys AG's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current Median PS Value is €0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score
Get the complete analysis for FRA:W33
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:W33 has been successfully added to your 